Frailty is a geriatric syndrome leading to physical deterioration including muscle wasting (sarcopenia) and unintentional weight loss. There are currently no approved therapies for frailty. Ghrelin is a hormone produced by the stomach that stimulates appetite centers in the brain. The purpose of this study is to determine the optimal subcutaneous ghrelin dose as a potential intervention for frail elderly individuals. We will examine food intake and metabolic parameters after placebo and ghrelin administration at three escalating subcutaneously administered doses.
This study is to determine the optimal ghrelin dose for use in a daily subcutaneous dosing study in frail individuals. Using data from our previous study and the published literature, we have designed a single blind, single dose administration study in which we will examine food intake after ghrelin administration and metabolic parameters (plasma glucose, insulin, free fatty acids, and cortisol) pre and post ghrelin administration.We have selected a dose range using our own and previously published studies from which we will determine subcutaneous doses to use in subsequent studies. The selection criteria for subsequent studies will be the dose that maximizes food intake by more than 30% without inducing hyperglycemia or raising cortisol levels. Participants must meet all inclusion criteria and have no exclusion criteria. Data will be analyzed after the first three participants have completed the protocol and used to inform dose modifications for the next three participants. Data from this portion of the study will be analyzed immediately after its completion, to allow updates to the design of the next study.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Enrollment
5
The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.
The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.
Clinical and Translational Research Center, University of Pennsylvania
Philadelphia, Pennsylvania, United States
Treatment Emergent Adverse Events
Number and type of treatment emergent adverse events
Time frame: 30 days following the last administration of study treatment.
Median Energy Intake
Median energy intake at breakfast, which was served 30 minutes post-placebo or ghrelin administration demonstrated at each dose level.
Time frame: 30 mins post-ghrelin or placebo
Percentage of Total Energy Intake Relative to Placebo
% of total energy relative to placebo - breakfast served 30 minutes post-placebo or ghrelin administration.
Time frame: 30 mins post-ghrelin or placebo
Growth Hormone
median growth hormone peak 30 minutes after placebo/ghrelin.
Time frame: 30 minutes after ghrelin administration
Cortisol Level
Cortisol response to ghrelin or placebo - levels at 0, 60 and 120 minutes after dosing
Time frame: 0, 60 and 120 minutes after dosing
Glucose Levels
Median fasting and peak postprandial Glucose levels (60 or 90 minutes from dosing) at placebo and at each ghrelin dose.
Time frame: 0 minutes (baseline) and 60 or 90 minutes from dosing
Insulin Level
Median fasting insulin levels at baseline and 90 minutes after dosing
Time frame: 0 and 90 minutes after dosing
Free Fatty Acid Level
Free Fatty Acid levels (mEq/L) at 60 and 90 minutes after meal (90 and 120 minutes)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 90 and 120 minutes after dosing